← Back to patent-cliff list
S-233107
Tier C — Watch / tradeS-233107
Laboratorios Servier Sl
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：ATXN3
Indications (approved)：运动障碍, Spinocerebellar ataxia
Regional status
US
-
2026-07-30
EU
Phase II
2026-06-30
China
-
Japan
-
2026-07-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of S-233107?
Approved indications include: 运动障碍, Spinocerebellar ataxia.
When does the S-233107 patent expire?
No public expiry year is available for S-233107 yet; this page updates once verified.
How do I get a quote for S-233107 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29